HOYA/PENTAX Medical Issues Statement Regarding U.S. Department of Justice Settlement
PR83593
MONTVALE, N.J. and TOKYO, April 8, 2020 /PRNewswire=KYODO JBN/ --
HOYA Corporation and a subsidiary through PENTAX Medical division, Pentax of
America, Inc. (collectively, "PENTAX" or "the Company"), today finalized a
Deferred Prosecution Agreement (DPA) with the U.S. Department of Justice (DOJ)
on issues related to the timely filing of Medical Device Reports (MDRs) for
PENTAX Medical's duodenoscopes and providing updated Instructions for Use
(IFUs) for several PENTAX Medical products. PENTAX first disclosed the DOJ
investigation in June 2015.
Logo - https://mma.prnewswire.com/media/1076915/Pentax_Logo.jpg
In the DPA, PENTAX acknowledged that it did not timely submit two required MDRs
to the U.S. Food and Drug Administration (FDA) for events in the US between
July 2013 and December 2014. In addition, PENTAX acknowledged that it failed to
send FDA approved IFUs for four types of endoscopes from April 2014 until
September 2015. PENTAX agreed to: pay a fine and forfeiture totaling $43
million; undertake new steps to enhance its compliance policies and procedures;
and regularly make certain certifications that PENTAX is meeting the
requirements of the DPA.
"PENTAX deeply regrets that it did not timely file the MDRs identified in the
DPA, as well as the failure to send the approved IFUs to customers. We accept
full responsibility for these failures," said David Woods, President of Pentax
of America, Inc.
The DPA does not allege any direct harm to patients as a result of the
disclosure failures or failure to send IFUs, and PENTAX acknowledged that it
failed to comply with the federal reporting requirements. The DPA does not
impact the availability of PENTAX Medical products and services worldwide.
"PENTAX Medical is committed to the highest standards of ethical behavior and
we are confident we can fulfill each of the obligations under this DPA to the
fullest extent necessary," said Gerry Bottero, Global President, PENTAX
Medical.
The full text of the DPA will be available on the PENTAX Medical website
(https://www.pentaxmedical.com/pentax/en/99/1/Compliance-and-Ethics ).
At PENTAX Medical, we have an unwavering commitment to our customers and their
patients to provide safe, high-quality products and services that offer true
value. To that end, we develop products and services that enable our customers
to improve clinical outcomes, reduce the cost of healthcare, and enhance the
experience they deliver to patients. This approach is demonstrated in how we
develop clinically relevant endoscopy products, advance cleaning procedures,
continuously improve our internal procedures, and empower our customers through
expert training and education programs. While we always strive to deliver on
our promises, how we achieve those results is equally as important.
About PENTAX Medical
PENTAX Medical is a division of HOYA Group. The company's mission is to improve
the standard of patient care and quality of healthcare delivery by providing
the best endoscopic products and services with a focus on QUALITY, CLINICALLY
RELEVANT INNOVATION, and SIMPLICITY.
Through providing endoscopic imaging devices and solutions to the global
medical community and with its headquartered in Japan, PENTAX Medical has a
worldwide focus and a strong presence with R&D, regional sales, service, and
in-country facilities in multiple regions around the globe.
PENTAX Medical's Triple Aim program strives to deliver on the commitment to
support its customers and their healthcare organization's wider objectives
through a transparent partnership and by providing the highest quality
solutions to help them reach their goals. Enabling customers to improve patient
outcomes by offering evidenced based solutions across the continuum of care,
dedicated to their needs. From screening through to therapy with full
scalabilities. Ensuring values by supporting the customers to improve their
efficiency and minimize their healthcare costs. Enriching patient and
provider's experience by empowering every member of the care team to achieve
optimal outcomes through products, education and support. For more information,
please visit: www.pentaxmedical.com. For more information, please visit
https://www.pentaxmedical.com.
About HOYA
Founded in 1941 in Tokyo, Japan, HOYA Corporation is a global technology and
med-tech company and a leading supplier of innovative high-tech and medical
products. HOYA's divisions and business units research and develop products
utilized in the healthcare and information technology fields.
In the healthcare field, we provide medical device products such as eyeglasses,
medical endoscopes, contact and intraocular lenses, orthopedic implants,
surgical/therapeutic devices and medical device reprocessing and disinfection
solutions. In the information technology field, we provide products such as
optical lenses, photomasks and blanks used in the manufacturing process for
semiconductor and LCD/OLED devices, text to speech, human resources and other
software solutions and critical components for the mass memory and cloud
storage industries. With over 150 offices and subsidiaries worldwide, HOYA
currently employs a multinational workforce of 37,000 people. For more
information, please visit http://www.hoya.com
Mariano Franco
1 (905) 580-7725
mariano.franco@pentaxmedical.com
SOURCE PENTAX Medical
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。